Table 2 Outcomes of MDRO carriers and non-carriers in patients with cirrhosis within one year of follow-up
Variables | MDRO− (n = 59) | MDRO+  (n = 29) | p-value |
|---|---|---|---|
SBP | 3 (5.1) | 2 (6.9) | 1.000 |
Infections other than SBP | 6 (10.2) | 4 (13.8) | 0.615 |
Hepatic encephalopathy | 2 (3.4) | 6 (20.7) | 0.008 |
Variceal bleeding | 2 (3.4) | 1 (3.4) | 1.000 |
Acute kidney injury | 13 (22.0) | 5 (17.2) | 0.600 |
Newly onset ascites | 3 (5.1) | 2 (6.9) | 1.000 |
Newly developed HCC | 4 (6.8) | 2 (6.9) | 1.000 |
Mortality | 1 (1.7) | 2 (6.9) | 0.252 |
Liver transplant | 1 (1.7) | 0 (0) | 1.000 |